Curis Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
15,002.00
9,843.50
7,878.40
7,527.00
9,898.00
10,428
Cost of Goods Sold (COGS) incl. D&A
339.30
339.60
405.80
592.00
731.00
740
Gross Income
14,662.70
9,503.90
7,472.70
6,935.00
9,167.00
9,688
SG&A Expense
24,079.10
25,366.20
39,605.70
46,985.00
58,927.00
39,021
EBIT
9,416.40
15,862.30
32,133.10
40,050.00
49,760.00
29,333
Unusual Expense
771.40
716.80
24,347.80
17,989.00
-
-
Non Operating Income/Expense
-
-
547.60
1.00
104.00
-
Interest Expense
3,841.60
3,748.40
3,325.00
2,777.00
3,966.00
3,926
Pretax Income
12,322.00
18,728.70
58,981.00
60,411.00
53,317.00
32,575
Consolidated Net Income
12,322.00
18,728.70
58,981.00
60,411.00
53,317.00
32,575
Net Income
12,322.00
18,728.70
58,981.00
60,411.00
53,317.00
32,575
Net Income After Extraordinaries
12,322.00
18,728.70
58,981.00
60,411.00
53,317.00
32,575
Net Income Available to Common
12,322.00
18,728.70
58,981.00
60,411.00
53,317.00
32,575
EPS (Basic)
0.75
1.10
2.40
2.25
1.80
0.98
Basic Shares Outstanding
16,467.90
17,194.90
24,673.00
26,557.10
29,826.70
33,118.40
EPS (Diluted)
0.75
1.09
2.39
2.27
1.79
0.98
Diluted Shares Outstanding
16,467.90
17,194.90
24,673.00
26,557.10
29,826.70
33,118.40
EBITDA
9,274.90
15,707.20
31,972.20
39,857.00
49,525.00
29,156
Non-Operating Interest Income
164.70
165.10
277.30
406.00
513.00
684

About Curis

View Profile
Address
4 Maguire Road
Lexington Massachusetts 02421
United States
Employees -
Website http://www.curis.com
Updated 07/08/2019
Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.